SCHEMBL1827353

SCHEMBL1827353

CCC(=O)Nc1ccc(COc2ccc(Cl)cc2C(F)(F)F)cc1C(=O)O

nearest known ligand 0.58

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
MRGPRX4 Q96LA9 11/20 0.58
KDM4E B2RXH2 4/20 0.51
MEN1 O00255 1/20 0.51
ALDH1A1 P00352 1/20 0.51
KMT2A Q03164 1/20 0.51
SMN1; SMN2 Q16637 1/20 0.51
RXRA P19793 1/20 0.46
RXRB P28702 1/20 0.46
RXRG P48443 1/20 0.46
MAPT P10636 1/20 0.45
GAA P10253 1/20 0.44
HTT P42858 1/20 0.44
PKM P14618 1/20 0.44
PTGER1 P34995 1/20 0.44
POLB P06746 1/20 0.43
G6PD P11413 1/20 0.43
LMNA P02545 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4437319 0.92 MRGPRX4 (0.56) MRGPRX4KDM4EMEN1ALDH1A1KMT2A
SCHEMBL1827561 0.89 RXRA (0.60) MRGPRX4KDM4ERXRARXRBRXRG
SCHEMBL1825124 0.89 MRGPRX4 (0.57) MRGPRX4KDM4EALDH1A1RXRARXRB
SCHEMBL1826345 0.88 POLB (0.47) MRGPRX4KDM4EMEN1KMT2ARXRA
SCHEMBL4605839 0.86 RXRA (0.57) MRGPRX4KDM4EMEN1ALDH1A1KMT2A
SCHEMBL1824562 0.86 MRGPRX4 (0.60) MRGPRX4KDM4EMEN1ALDH1A1KMT2A
SCHEMBL1822709 0.86 MRGPRX4 (0.68) MRGPRX4KDM4EMEN1ALDH1A1KMT2A
SCHEMBL1822939 0.86 MRGPRX4 (0.56) MRGPRX4KDM4EALDH1A1KMT2ARXRA
SCHEMBL1822283 0.84 MRGPRX4 (0.56) MRGPRX4KDM4EMEN1ALDH1A1KMT2A
SCHEMBL1824100 0.84 MRGPRX4 (0.71) MRGPRX4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8461205-B2 Anthranilic acid derivatives CHELSEA THERAPEUTICS, INC. (US) 2013-06-11 US claimed
US-20120283326-A1 ANTHRANILIC ACID DERIVATIVES CHELSEA THERAPEUTICS, INC. 2012-11-08 US claimed
US-8263658-B2 Anthranilic acid derivatives CHELSEA THERAPEUTICS, INC. (US) 2012-09-11 US claimed
EP-2118051-B1 NEW COMPOUNDS, METHODS FOR THEIR PREPARATION AND USE THEREOF CHELSEA THERAPEUTICS INC (US) 2011-05-04 EP claimed
US-20100029767-A1 ANTHRANILIC ACID DERIVATIVES Chelsea Therapeutics, Inc 2010-02-04 US claimed
US-8461205-B2 Anthranilic acid derivatives CHELSEA THERAPEUTICS, INC. (US) 2013-06-11 US disclosed
US-20120283326-A1 ANTHRANILIC ACID DERIVATIVES CHELSEA THERAPEUTICS, INC. 2012-11-08 US disclosed
US-8263658-B2 Anthranilic acid derivatives CHELSEA THERAPEUTICS, INC. (US) 2012-09-11 US disclosed
EP-2118051-B1 NEW COMPOUNDS, METHODS FOR THEIR PREPARATION AND USE THEREOF CHELSEA THERAPEUTICS INC (US) 2011-05-04 EP disclosed
US-20100029767-A1 ANTHRANILIC ACID DERIVATIVES Chelsea Therapeutics, Inc 2010-02-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120283326-A1 ANTHRANILIC ACID DERIVATIVES ACOX3, BCL3, AOC3 MRGPRX4 1127/4885KDM4E 4207/4885MEN1 1718/4885
US-20100029767-A1 ANTHRANILIC ACID DERIVATIVES ACOX3, BCL3, AOC3 MRGPRX4 1135/4885KDM4E 4172/4885MEN1 1752/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.